{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:49:24Z","timestamp":1747190964861,"version":"3.40.5"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Virology"],"published-print":{"date-parts":[[2022,12,6]]},"abstract":"<jats:p>Introduction. COVID-19 has been associated with the overactivation of the immune system; interleukin-6 (IL-6) seems to have a key role, which made its moderation to be proposed as a therapeutic blank. Tocilizumab has been used as part of treatments to modulate the immune response to infections caused by COVID-19. Material and Methods. An observational, descriptive, retrospective, and transversal study was carried out in patients diagnosed with moderate-severe COVID-19 who were hospitalized in the 251 General Regional Hospital from March to December 2020. Results. A review of 700 files corresponding to hospitalized patients was carried out, and a sample of 70 patients who met the inclusion criteria proposed for this protocol was obtained. Among the comorbidities associated with the disease, it was found that hypertensive patients have a higher mortality rate: 62% died and so did 59% of those who needed invasive respiratory support. As regards admission tests, statistical significance was found for the figures of leukocytes, neutrophils, glomerular filtration rate, and PCR. Conclusion. The use of this drug benefits mainly young nonhypertensive patients with a moderate disease and preserved renal functions with no need for invasive respiratory support, regardless of other comorbidities.<\/jats:p>","DOI":"10.1155\/2022\/6880405","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:21:28Z","timestamp":1670361688000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-0363","authenticated-orcid":true,"given":"Yessica","family":"Bernal Luna","sequence":"first","affiliation":[{"name":"Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico"},{"name":"Universidad Aut\u00f3noma del Estado de M\u00e9xico, Facultad de Medicina, Toluca, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Esquivel Loza","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-5955","authenticated-orcid":true,"given":"Jos\u00e9 de Jes\u00fas","family":"Gardu\u00f1o Garc\u00eda","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico"},{"name":"Universidad Aut\u00f3noma del Estado de M\u00e9xico, Facultad de Medicina, Toluca, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2001017"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30251-8"},{"article-title":"WHO Coronavirus Disease (COVID-19) Dashboard","year":"2020","author":"No Title [Internet]","key":"3"},{"author":"CONACyT","key":"4","article-title":"Covid-19 M\u00e9xico [Internet]. 2022 [cited 2022 Nov 7]"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-020-00359-4"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12908"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.08.006"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5735546"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104444"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.127"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s1828"},{"key":"15","first-page":"1","article-title":"Algoritmos interinos para la atenci\u00f3n del COVID-19","author":"Instituto Mexicano del Seguro Social","year":"2020","journal-title":"Gob M\u00e9xico"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.04.035"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.034"},{"issue":"(4)","key":"18","first-page":"193","article-title":"To Dispense or Not to Dispense: Lessons to Be Learnt from Ethical Challenges Faced by Pharmacists in the COVID-19 Pandemic","volume":"21","author":"S. Cox","year":"2020","journal-title":"Dev World Bioeth"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4989"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.021"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100418"},{"issue":"10285","key":"23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet (London, England)"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00081-3"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2030340"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.24875\/ric.21000404"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99291-z"}],"container-title":["Advances in Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/av\/2022\/6880405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/av\/2022\/6880405.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/av\/2022\/6880405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:21:31Z","timestamp":1670361691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/av\/2022\/6880405\/"}},"subtitle":[],"editor":[{"given":"Majid","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":27,"alternative-id":["6880405","6880405"],"URL":"https:\/\/doi.org\/10.1155\/2022\/6880405","relation":{},"ISSN":["1687-8647","1687-8639"],"issn-type":[{"type":"electronic","value":"1687-8647"},{"type":"print","value":"1687-8639"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}